These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 12450955)

  • 1. SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder.
    Rinne T; van den Brink W; Wouters L; van Dyck R
    Am J Psychiatry; 2002 Dec; 159(12):2048-54. PubMed ID: 12450955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonin transporter polymorphism and fluoxetine effect on impulsiveness and aggression in borderline personality disorder.
    Silva H; Iturra P; Solari A; Villarroel J; Jerez S; Vielma W; Montes C; Pumarino L; Roa N
    Actas Esp Psiquiatr; 2007; 35(6):387-92. PubMed ID: 17597424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder.
    Zanarini MC; Frankenburg FR; Parachini EA
    J Clin Psychiatry; 2004 Jul; 65(7):903-7. PubMed ID: 15291677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder.
    Hollander E; Swann AC; Coccaro EF; Jiang P; Smith TB
    Am J Psychiatry; 2005 Mar; 162(3):621-4. PubMed ID: 15741486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder.
    Hollander E; Allen A; Lopez RP; Bienstock CA; Grossman R; Siever LJ; Merkatz L; Stein DJ
    J Clin Psychiatry; 2001 Mar; 62(3):199-203. PubMed ID: 11305707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind, placebo-controlled trial of fluvoxamine in binge eating disorder: a high placebo response.
    Pearlstein T; Spurell E; Hohlstein LA; Gurney V; Read J; Fuchs C; Keller MB
    Arch Womens Ment Health; 2003 Apr; 6(2):147-51. PubMed ID: 12720065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial.
    Goodman WK; Kozak MJ; Liebowitz M; White KL
    Int Clin Psychopharmacol; 1996 Mar; 11(1):21-9. PubMed ID: 8732310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder.
    Hollander E; Koran LM; Goodman WK; Greist JH; Ninan PT; Yang H; Li D; Barbato LM
    J Clin Psychiatry; 2003 Jun; 64(6):640-7. PubMed ID: 12823077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidenced-based pharmacologic treatment of borderline personality disorder: a shift from SSRIs to anticonvulsants and atypical antipsychotics?
    Abraham PF; Calabrese JR
    J Affect Disord; 2008 Nov; 111(1):21-30. PubMed ID: 18304647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline.
    Waldinger MD; Hengeveld MW; Zwinderman AH; Olivier B
    J Clin Psychopharmacol; 1998 Aug; 18(4):274-81. PubMed ID: 9690692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: A randomized double-blind, placebo-controlled study.
    Zheng H; Jia F; Han H; Wang S; Guo G; Quan D; Li G; Huang H
    Eur Neuropsychopharmacol; 2019 Mar; 29(3):397-404. PubMed ID: 30595354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder.
    Nair NP; Bakish D; Saxena B; Amin M; Schwartz G; West TE
    Anxiety; 1996; 2(4):192-8. PubMed ID: 9160622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients.
    Asnis GM; Hameedi FA; Goddard AW; Potkin SG; Black D; Jameel M; Desagani K; Woods SW
    Psychiatry Res; 2001 Aug; 103(1):1-14. PubMed ID: 11472786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation adverse events induced by the selective serotonin reuptake inhibitor fluvoxamine in children and adolescents.
    Reinblatt SP; DosReis S; Walkup JT; Riddle MA
    J Child Adolesc Psychopharmacol; 2009 Apr; 19(2):119-26. PubMed ID: 19364290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: a preliminary study.
    Niitsu T; Fujisaki M; Shiina A; Yoshida T; Hasegawa T; Kanahara N; Hashimoto T; Shiraishi T; Fukami G; Nakazato M; Shirayama Y; Hashimoto K; Iyo M
    J Clin Psychopharmacol; 2012 Oct; 32(5):593-601. PubMed ID: 22926591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study.
    Stein MB; Fyer AJ; Davidson JR; Pollack MH; Wiita B
    Am J Psychiatry; 1999 May; 156(5):756-60. PubMed ID: 10327910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression.
    Thase ME; Nierenberg AA; Vrijland P; van Oers HJ; Schutte AJ; Simmons JH
    Int Clin Psychopharmacol; 2010 Jul; 25(4):189-98. PubMed ID: 20531012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial.
    Riddle MA; Reeve EA; Yaryura-Tobias JA; Yang HM; Claghorn JL; Gaffney G; Greist JH; Holland D; McConville BJ; Pigott T; Walkup JT
    J Am Acad Child Adolesc Psychiatry; 2001 Feb; 40(2):222-9. PubMed ID: 11211371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical evaluation of treatment with fluvoxamine, a selective serotonin reuptake inhibitor in children with autistic disorder].
    Fukuda T; Sugie H; Ito M; Sugie Y
    No To Hattatsu; 2001 Jul; 33(4):314-8. PubMed ID: 11494573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder.
    Heidari M; Zarei M; Hosseini SM; Taghvaei R; Maleki H; Tabrizi M; Fallah J; Akhondzadeh S
    Int Clin Psychopharmacol; 2014 Nov; 29(6):344-50. PubMed ID: 24850229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.